Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 13.28% is 20% below its 5-year average of 16.61%, around the middle of its 5-year range (-0.87%–24.34%).
37.96% above its 12-month average of 9.63%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -0.87%.
EBITDA MARGIN
13.28%
EBITDA MARGIN AVG TTM
9.63%
EBITDA MARGIN AVG 3Y
13.71%
EBITDA MARGIN AVG 5Y
16.61%
EBITDA MARGIN AVG 10Y
16.56%
EBITDA MARGIN AVG 15Y
14.48%
EBITDA MARGIN AVG 20Y
13.94%
CURRENT VS TTM AVG
+37.96%
CURRENT VS 3Y AVG
-3.12%
CURRENT VS 5Y AVG
-20.03%
CURRENT VS 10Y AVG
-19.83%
CURRENT VS 15Y AVG
-8.28%
CURRENT VS 20Y AVG
-4.71%
Bruker Corporation
Market Cap
$8.91B
EBITDA Margin
13.28%
TTM Avg
9.63%
3Y Avg
13.71%
5Y Avg
16.61%
Market Cap
$9.01B
EBITDA Margin
-25.09%
TTM Avg
-47.89%
3Y Avg
-132.36%
5Y Avg
-132.36%
Market Cap
$8.85B
EBITDA Margin
-340.97%
TTM Avg
-141.29%
3Y Avg
-228.68%
5Y Avg
-264.44%
Market Cap
$8.79B
EBITDA Margin
14.74%
TTM Avg
-8194.33%
3Y Avg
-4134.44%
5Y Avg
-2789.78%
Market Cap
$9.21B
EBITDA Margin
13.28%
TTM Avg
13.13%
3Y Avg
16.37%
5Y Avg
17.13%
Market Cap
$8.67B
EBITDA Margin
-870.12%
TTM Avg
-705.14%
3Y Avg
-488.60%
5Y Avg
-370.00%
Market Cap
$8.41B
EBITDA Margin
-3.14%
TTM Avg
-1.08%
3Y Avg
-5.02%
5Y Avg
-19.32%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bruker Corporation (BRKRP) | $8.91B | 13.28% | 9.63% | 13.71% | 16.61% |
| Axsome Therapeutics, Inc. (AXSM)vs › | $9.01B | -25.09% | -47.89% | -132.36% | -132.36% |
| Protagonist Therapeutics, Inc. (PTGX)vs › | $8.85B | -340.97% | -141.29% | -228.68% | -264.44% |
| Arrowhead Pharmaceuticals, Inc. (ARWR)vs › | $8.79B | 14.74% | -8194.33% | -4134.44% | -2789.78% |
| Bruker Corporation (BRKR)vs › | $9.21B | 13.28% | 13.13% | 16.37% | 17.13% |
| Kymera Therapeutics, Inc. (KYMR)vs › | $8.67B | -870.12% | -705.14% | -488.60% | -370.00% |
| Insulet Corp. (PODD)vs › | $9.38B | 21.67% | 20.24% | 16.36% | 15.66% |
| Vaxcyte, Inc. (PCVX)vs › | $9.50B | N/A | N/A | N/A | N/A |
| Oscar Health, Inc. (OSCR)vs › | $8.41B | -3.14% | -1.08% | -5.02% | -19.32% |
| Krystal Biotech, Inc. (KRYS)vs › | $9.63B | 43.13% | 34.03% | -45.57% | -45.57% |
Gross Margin
46.7%
EBITDA Margin
13.3%
Operating Margin
3.6%
Net Margin
-2.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -0.87% |
| 2026-03-31 | 12.55% |
| 2025-12-31 | 17.39% |
| 2025-09-30 | 10.54% |
| 2025-06-30 | 8.53% |
| 2025-03-31 | 10.26% |
| 2024-12-31 | 12.76% |
| 2024-09-30 | 13.78% |
| 2024-06-30 | 11.65% |
| 2024-03-31 | 13.79% |
| 2023-12-31 | 16.48% |
| 2023-09-30 | 20.34% |
| 2023-06-30 | 16.44% |
| 2023-03-31 | 21.57% |
| 2022-12-31 | 21.95% |
| 2022-09-30 | 24.34% |
| 2022-06-30 | 16.23% |
| 2022-03-31 | 19.87% |
| 2021-12-31 | 22.66% |
| 2021-09-30 | 22.24% |
| 2021-06-30 | 18.78% |
| 2021-03-31 | 20.08% |
| 2020-12-31 | 23.79% |
| 2020-09-30 | 19.89% |
| 2020-06-30 | 13.87% |
| 2020-03-31 | 8.35% |
| 2019-12-31 | 23.07% |
| 2019-09-30 | 20.48% |
| 2019-06-30 | 14.87% |
| 2019-03-31 | 13.20% |
| 2018-12-31 | 22.22% |
| 2018-09-30 | 18.22% |
| 2018-06-30 | 14.74% |
| 2018-03-31 | 12.49% |
| 2017-12-31 | 20.62% |
| 2017-09-30 | 15.38% |
| 2017-06-30 | 11.93% |
| 2017-03-31 | 13.69% |
| 2016-12-31 | 19.31% |
| 2016-09-30 | 15.13% |
| 2016-06-30 | 9.12% |
| 2016-03-31 | 12.57% |
| 2015-12-31 | 17.57% |
| 2015-09-30 | 10.48% |
| 2015-06-30 | 11.31% |
| 2015-03-31 | 8.12% |
| 2014-12-31 | 11.14% |
| 2014-09-30 | 5.36% |
| 2014-06-30 | 10.98% |
| 2014-03-31 | 8.45% |
| 2013-12-31 | 13.93% |
| 2013-09-30 | 10.64% |
| 2013-06-30 | 12.86% |
| 2013-03-31 | 6.96% |
| 2012-12-31 | 10.79% |
| 2012-09-30 | 16.57% |
| 2012-06-30 | 8.82% |
| 2012-03-31 | 11.83% |
| 2011-12-31 | 14.17% |
| 2011-09-30 | 9.15% |
| 2011-06-30 | 9.82% |
| 2011-03-31 | 8.29% |
| 2010-12-31 | 15.36% |
| 2010-09-30 | 12.99% |
| 2010-06-30 | 12.83% |
| 2010-03-31 | 12.39% |
| 2009-12-31 | 23.20% |
| 2009-09-30 | 12.49% |
| 2009-06-30 | 10.77% |
| 2009-03-31 | 9.15% |
| 2008-12-31 | 17.87% |
| 2008-09-30 | 9.47% |
| 2008-06-30 | 9.13% |
| 2008-03-31 | 16.57% |
| 2007-12-31 | 18.21% |
| 2007-09-30 | 9.06% |
| 2007-06-30 | 5.78% |
| 2007-03-31 | 7.37% |
| 2006-12-31 | 21.55% |
| 2006-09-30 | 8.51% |
| 2006-06-30 | 4.67% |
| 2006-03-31 | 5.32% |
| 2005-12-31 | 15.97% |
| 2005-09-30 | 4.62% |
| 2005-06-30 | 1.28% |
| 2005-03-31 | 3.97% |
| 2004-12-31 | 2.71% |
| 2004-09-30 | 0.38% |
| 2004-06-30 | -8.23% |
| 2004-03-31 | 2.88% |
| 2003-12-31 | 15.98% |
| 2003-09-30 | -1.99% |
| 2003-06-30 | 0.99% |
| 2003-03-31 | 9.76% |
| 2002-12-31 | 20.90% |
| 2002-09-30 | 8.95% |
